Etamicastat clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses etamicastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses etamicastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453CompletedPhase 1Bial - Portela C S.A.NCT03099226Written as BIA 5-453
- Bioavailability Study of BIA 5-453CompletedPhase 1Bial - Portela C S.A.NCT03090568Written as BIA 5-453
- Pharmacokinetics of BIA 5-453 and Its MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT03090724Written as BIA 5-453
- Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT03014375Written as BIA-5-453
- Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453CompletedPhase 1Bial - Portela C S.A.NCT02845037Written as BIA 5-453
- Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453CompletedPhase 1Bial - Portela C S.A.NCT02840565Written as BIA 5-453
Codes
What other systems call etamicastat · ClinicalTrials.gg INT004886
- MeSH (NLM) C509002etamicastatOne source NLM
- UNII (FDA) 9X96V6DBU4ETAMICASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27273344etamicastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90846EtamicastatOne source FDA
- DrugBank DB15288One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509002 | etamicastat | One source NLM |
| UNII (FDA) | 9X96V6DBU4 | ETAMICASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27273344 | etamicastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90846 | Etamicastat | One source FDA |
| DrugBank | DB15288 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.